Mr. Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment.
Dr. Leslie Mesen is a leader in the field of Anti-Aging Medicine in Latin America. Like so many in his profession, he grew up as the son of medical professionals. His father a medical doctor and his mother a medical professional and PhD. Literally from day one, Dr. Mesen saw both the good and the bad of modern medicine. Dr. Mesen led a normal childhood, but always was intrigued by why people grow old. He often reflects asking why do people get old? How does the aging process work? These questions, as with many, remained in the back of his mind through life, medical school, to where he is today, concentrating his practice in the field of Anti-Aging Medicine.
The Founder and CEO of the Nanotechnology World Network, Marine Le Bouar, worked for 20 years in International Sales & Business Development before devoting herself entirely to her true passion: nanotechnology.? Over the past few years, she has built a solid network of professionals in the industry, and is now bringing them together in this resourceful association.? She is regularly called upon by governmental agencies or large investment funds across the world to provide them with her unique take on the pulse of this industry, and to provide her vision of the next few years as the nanotechnology future unfolds.
Ajan Reginald founded Celixir with Professor Sir Martin Evans in 2009 and has served as the company’s Chief Executive Officer since inception. He is an inventor of Celixir’s core technology, discovered Heartcel and Tendoncel and designed and led the early clinical trials. Under Ajan’s leadership, the company has grown from 1 employee in 2009 to ~70 FTEs in EU, US and Asia and has completed five successful funding rounds. These rounds include crowd funding in 2014 and successful institutional funding rounds in 2016 and 2017. In addition to this, Ajan led the negotiation and completion of Celixir’s partnership with Daiichi Sankyo (DS) in 2016 and Co-Chairs the DS-Celixir Joint Steering Committee. Before Celixir, Ajan served as the Global Head of Emerging Technologies for Roche Group Research. Here, he was tasked with analysing and acquiring / partnering the next class of breakthrough medicines and innovative medical technologies. Ajan began his career at Roche Pharma. Here, he partnered as a Business Development Director in the Pharma M&A group, leading the analysis and transaction teams for large strategic partnerships and acquisitions. In 2007, he was awarded the Roche Gold Olympiad for a $1.3B Alnylam transaction. Ajan served as a consultant to Pharmaceutical clients in the US and Europe at the Boston Consulting Group, developing intellectual property strategy for clients in multiple industries. Ajan is a Fulbright Scholar and alumni of Harvard Business School (AMP), University of Oxford (MSC, Experimental Therapeutics), Kellogg Business School (MBA) and London University (BDS). He plays hockey and has represented England at World and European Masters Hockey Championships.
Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA and he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University(CSU), Irvine, California, USA. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research institutes around the world.
Biography Professor Vladimir S. Sukhorukov M.D., Ph.D., D.Sci. Professor of the Center for Personalized Medicine - Sechenov Medical University (Moscow); Head of the General Pathology Department - Veltischev Pediatric Institute of Pirogov Medical University (Moscow); Among main scientific achievements: the identification of the stimulating effect of low-intensity laser on the regeneration of germ cells, the description of pathological complex changes in skeletal muscle tissue in mitochondrial diseases in children, the development of methodological approaches to the laboratory diagnostics of primary and secondary disorders of cellular energy metabolism, the description of the phenomenon of "energy deficient diathesis", development of the hypothesis of adaptive and compensatory proliferative potential of mitochondria in humans. Important point of his activity now - an organization of investigations in different aspects of pediatric pathology (mitochondrial diseases, other inherited metabolic diseases, neuromuscular diseases, and the like) with use of chromatography, mass-spectroscopy, molecular-genetic, immunohistochemical studies, electron microscopy and other.
pediatric pathology, histology, mitochondrial diseases, inherited metabolic diseases, neuromuscular diseases
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at caused of cardiovascular diseases and a year at Johns Hopkins Medical School looking at treatment of liver. He published more than 647 peer-reviewed research papers, and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology. He has over 15,000 media report from his achievement, include BBC, ITV, WSJ, CNN, and many more. Currently he is working on development and commercialisation of human organs using graphene based nanocomposite materials and stem cells technology.
Nanotechnology and Regenerative Medicine
Dr. Jaba Tkemaladze Ph.D. is CEO of Longevity Alliance Georgia. He was previously Research scientist at State Institute of Morphology, Adviser at The Ministry of Defense of Georgia. His papers include: Programming and Implementation of Age-Related Changes, Gerontology research in Georgia, Potential role of centrioles in determining the morphogenetic status of animal somatic cells, Centriolar mechanisms of differentiation and replicative aging of higher animal cell, Centrosomal hypothesis of cellular aging and differentiation, Discovery of centrosomal RNA and centrosomal hypothesis of cellular aging and differentiation, and Centriole, differentiation, and senescence.
Cell Therapy, Gene-edited Cells, CRISPR, Synthetic Biology, in-house platform technologies, CVS and Oncology medicines
CEO and Founder of Biotechnology and Regenerative Medicine at RegenerAge International ™ . Vice President of International Clinical Development for Bioquark, Inc. and Chief Clinical Officer at ReAnima™ Advanced Biosciences . Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine , Visiting Scholar at University of North Carolina at Chapel Hill . Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida.
Walter Bini has completed his Diploma at Westminster School, Simsbury Conn. USA and Post-graduate degree at Universidad de Zaragoza, Facultad de Medicina, Zaragoza-Spain. In 2014, he was the Middle East Chairman of ISLASS. He was Head of Neurosurgery at Sheikh Khalifa General Hospital, UAQ-UAE from 2014-2016. Currently, he is Consultant Neurosurgeon in Orthopedic department, spine section of Lanzo Hospital COF, Lanzo d’Intelvi in Italy and also Visiting Consultant Neurosurgeon in Orthopedic department at Healthpoint Hospital, UAE.
Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing Clinical Medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics Departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993). He is now retired and living in the Adirondacks in New York, USA.